摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氨基甲酰-1-[5-O-(羟基膦酸)-alpha-D-呋喃核糖基]吡啶鎓 | 7298-94-4

中文名称
3-氨基甲酰-1-[5-O-(羟基膦酸)-alpha-D-呋喃核糖基]吡啶鎓
中文别名
α-烟酰胺单核苷酸;α-烟酰胺核糖一磷酸酯
英文名称
α-NMN
英文别名
alpha-Nicotinamide mononucleotide;[(2R,3S,4R,5S)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
3-氨基甲酰-1-[5-O-(羟基膦酸)-alpha-D-呋喃核糖基]吡啶鎓化学式
CAS
7298-94-4
化学式
C11H15N2O8P
mdl
——
分子量
334.222
InChiKey
DAYLJWODMCOQEW-CDLYGTGVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    115-122°C
  • 溶解度:
    加热、超声处理轻微溶于甲醇、轻微溶于水

计算性质

  • 辛醇/水分配系数(LogP):
    -3.5
  • 重原子数:
    22
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.454
  • 拓扑面积:
    166
  • 氢给体数:
    4
  • 氢受体数:
    8

SDS

SDS:02ffc6503236a913dc5a8f298e14fb1e
查看

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF IN THE TREATMENT AND PREVENTION OF AN ANTINEOPLASTIC-INDUCED TOXICITY<br/>[FR] DÉRIVÉS DE NICOTINAMIDE MONONUCLÉOTIDE ET LEUR UTILISATION DANS LE TRAITEMENT ET LA PRÉVENTION D'UNE TOXICITÉ INDUITE PAR UN ANTINÉOPLASIQUE
    申请人:NUVAMID SA
    公开号:WO2022029287A1
    公开(公告)日:2022-02-10
    The present invention relates to nicotinamide mononucleotide derivatives of Formula (I) for use in the treatment and/or prevention of an antineoplastic-induced toxicity. The present invention further relates to pharmaceutical compositions comprising compounds of Formula (I) for use in the treatment and/or prevention of an antineoplastic-induced toxicity.
    本发明涉及公式(I)的烟酰胺单核苷酸衍生物,用于治疗和/或预防抗肿瘤药物引起的毒性。本发明还涉及含有公式(I)化合物的制药组合物,用于治疗和/或预防抗肿瘤药物引起的毒性。
  • [EN] NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION<br/>[FR] DÉRIVÉS MONONUCLÉOTIDIQUES NICOTINAMIDES ET LEUR UTILISATION POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE À FRACTION D'ÉJECTION PRÉSERVÉE
    申请人:NUVAMID SA
    公开号:WO2022263625A1
    公开(公告)日:2022-12-22
    The present invention relates to nicotinamide mononucleotide derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, for use in the treatment of heart failure with preserved ejection fraction (HFpEF) in a subject in need thereof.
    本发明涉及公式(I)的烟酰胺单核苷酸衍生物或其药学上可接受的盐或溶剂,用于治疗需要治疗心脏收缩功能保留型心力衰竭(HFpEF)的患者。
  • [EN] NICOTINAMIDE MONONUCLEOTIDE DERIVATIVES AND USE THEREOF IN THE STIMULATION OF THE EXPRESSION OF FETAL HEMOGLOBIN<br/>[FR] DÉRIVÉS DE NICOTINAMIDE MONONUCLÉOTIDE ET LEUR UTILISATION DANS LA STIMULATION DE L'EXPRESSION DE L'HÉMOGLOBINE FOETALE
    申请人:NUVAMID SA
    公开号:WO2022129536A1
    公开(公告)日:2022-06-23
    The present invention relates to nicotinamide mononucleotide derivatives of Formula (I) for use in the stimulation of the expression of fetal hemoglobin. The present invention further relates to pharmaceutical compositions comprising compounds of Formula (I) for use in the stimulation of the expression of fetal hemoglobin.
    本发明涉及公式(I)的烟酰胺单核苷酸衍生物,用于刺激胎儿血红蛋白的表达。本发明还涉及含有公式(I)化合物的药物组合物,用于刺激胎儿血红蛋白的表达。
  • An efficient chemical and enzymic synthesis of nicotinamide adenine dinucleotide (NAD+)
    作者:David R. Walt、Mark A. Findeis、Victor M. Rios-Mercadillo、Jacques Auge、George M. Whitesides
    DOI:10.1021/ja00313a045
    日期:1984.1
查看更多

同类化合物

烟酸单核苷酸 β-烟酰胺单核苷酸 3-氨基甲酰-1-[5-O-(羟基膦酸)-alpha-D-呋喃核糖基]吡啶鎓 but-3-yn-l-yl (((2R,3S,4R,5R)-5-(3-carbamoylpyridin-l-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl) phosphate nicotinamide mononucleotide nicotinate D-ribonucleotide 1,4-dihydronicotinamide adenine dinucleotide α-Nicotinamid-mononucleotid 3-Carbamoyl-1-((2S,3S,4R,5S)-3,4-dihydroxy-5-phosphonooxymethyl-tetrahydro-furan-2-yl)-pyridinium NMNH Nicotinamide-benzimidazole dinucleotide [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[2-(2-methoxyphenoxy)ethoxy]ethyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[1-[5-(naphthalen-1-ylmethylamino)-5-oxopentyl]triazol-4-yl]ethyl phosphate 2-(1-adamantyl)ethyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate 2-[1-[5-(benzhydrylamino)-5-oxopentyl]triazol-4-yl]ethyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[2-(3-methylphenoxy)ethoxy]ethyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-phenylethyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 5-phenoxypentyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[1-[5-oxo-5-[(4-phenylphenyl)methylamino]pentyl]triazol-4-yl]ethyl phosphate 2-(1-benzyltriazol-4-yl)ethyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl 2-[2-(3-fluorophenoxy)ethoxy]ethyl phosphate butyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate 1-(3'-deoxy-3'-fluoro-β-D-xylofuranosyl)nicotinamide-5'-phosphate 1-(3'-azido-3'-deoxy-β-D-ribofuranosyl)nicotinamide-5'-(benzyl phosphate) 1-(3'-azido-3'-deoxy-β-D-ribofuranosyl)nicotinamide-5'-(butyl phosphate) [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl methyl phosphate beta-Nicotinamide mononucleotide [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl methyl hydrogen phosphate 1-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid 1-[(2R,3S,4R,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid [(2R,3S,4R,5R)-5-(benzimidazol-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono phosphate [[(2R,3R,4R,5R)-5-amino-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate 1-[(2R,3R,4R,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid [(2S,3S,4R,5S)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate [amino-[5-azanidyl-1-[5-[[[[5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxymethyl]-4-hydroxy-3-phosphonooxyoxolan-2-yl]imidazolidine-4,5-diid-4-yl]methyl]azanide [(2S,3R,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate 1-[(2S,3S,4R,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid Pyridinium, 3-carboxy-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[(2S,3R,4S,5S)-3,4-dihydroxy-5-(4-naphthalen-1-yltriazol-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphate [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[(2S,3R,4S,5S)-3,4-dihydroxy-5-(4-phenyltriazol-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphate [[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2S,3R,4S,5S)-3,4-dihydroxy-5-(4-phenyltriazol-1-yl)oxolan-2-yl]methyl hydrogen phosphate β-nicotinamide mononucleotide [(2R,3R,4S,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate 1-[(2R,3R,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid [(2S,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate 1-[(2R,3S,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid 1-[(2S,3R,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid [(2S,3S,4S,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate [(2S,3S,4S,5S)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate 1-[(2S,3S,4S,5S)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxylic acid